According to one of the test developers, its technology has the potential to enable the manufacturing of tests where they are needed in low-resource settings.
The firm's CEO said that the deprioritization of its submission for a standalone SARS-CoV-2 assay running on its Verigene I molecular diagnostic instrument is puzzling.
With new platforms in its plans, Accelerate will target hospitals that have a bacterial identification method but want to add rapid susceptibility testing.
The firm anticipates completing the study in about 18 months and then applying for US Food and Drug Administration clearance for its multimodal platform and assays.
Emerging technologies included biosensors, host response tests using different types of biomarkers, and new ways to make and develop antigen, antibody, and PCR tests.
